De Spirito Marco, Palmieri Valentina, Perini Giordano, Papi Massimiliano
Department of Neuroscience, Universita Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico IRCSS, Fondazione Policlinico Universitario "A. Gemelli", Largo A. Gemelli 8, 00168 Rome, Italy.
Bioengineering (Basel). 2024 Jun 28;11(7):664. doi: 10.3390/bioengineering11070664.
Recent advancements in 3D bioprinting and microfluidic lab-on-chip systems offer promising solutions to the limitations of traditional animal models in biomedical research. Three-dimensional bioprinting enables the creation of complex, patient-specific tissue models that mimic human physiology more accurately than animal models. These 3D bioprinted tissues, when integrated with microfluidic systems, can replicate the dynamic environment of the human body, allowing for the development of multi-organ models. This integration facilitates more precise drug screening and personalized therapy development by simulating interactions between different organ systems. Such innovations not only improve predictive accuracy but also address ethical concerns associated with animal testing, aligning with the three Rs principle. Future directions include enhancing bioprinting resolution, developing advanced bioinks, and incorporating AI for optimized system design. These technologies hold the potential to revolutionize drug development, regenerative medicine, and disease modeling, leading to more effective, personalized, and humane treatments.
3D生物打印和微流控芯片实验室系统的最新进展为解决生物医学研究中传统动物模型的局限性提供了有前景的解决方案。三维生物打印能够创建复杂的、针对患者的组织模型，比动物模型更准确地模拟人体生理机能。这些3D生物打印组织与微流控系统集成后，能够复制人体的动态环境，从而开发多器官模型。这种集成通过模拟不同器官系统之间的相互作用，有助于进行更精确的药物筛选和个性化治疗开发。此类创新不仅提高了预测准确性，还解决了与动物试验相关的伦理问题，符合3R原则。未来的发展方向包括提高生物打印分辨率、开发先进的生物墨水以及引入人工智能以优化系统设计。这些技术有望彻底改变药物开发、再生医学和疾病建模，带来更有效、个性化和人道的治疗方法。
